of raw materials from abroad was done through the purchase department of Merck Darmstard and, (c) that 80 per cent to 90 per cent of items marketed as Laboratory Chemicals by Merck India are repacked straight either from imported or indigenous raw materials.

The matter was taken up with the corn-par, y who has clarified that more than 40 qualified chemists are working on Laboratory Chemicals. The company has denied the allegation that they are merely repacking the imported or indigenous raw materials and stated that their activities involve highly sophisticated technology and conforms to the industrial licence issued to them for laboratory chemicals and re-agents. The company has also clarified that the purchase of raw materials is not made through the purchase department of M/s. Merck Darmstard (the for-eign collaboration) and that they have their own purchase department through which they organise all purchases. The company has further clarified that in terms of licence for laboratory chemicals granted to them, no unfair business practices is being adopted.

Show cause notice for marketing products without price approval

2192. SHRIMATI MONIKA DAS: Will the Minister of INDUSTRY be pleased to state:

(a) whether his attention wa$_s$ drawn to the news item captioned 'show cause no tices to 2 drug companies' which appeared in the 'Financial Express' of 21st Novem ber, 1985;

(b) whether it is $_a$ fact that Government have issued nonces *to* drug companies who are marketing their products without obtaining price approval;

(c) if so, names of the companies and when it came to the notice of Government that each of thos$_e$ companies have crossed the exempted limit of sales turn over of Rupees Fifty lacs per annum;

(d) whether it is also a fact that there are number of drug companies who are marketing their products without price approval even when the sales turn over of each of 'heir predicts has crossed Rupees one crore; and

(e) if $_s$o, names of such products and their manufacturers?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAI-CHANDRA SINGH); (a) Yes, Sir.

(b) to (e) A large number of notices have been issued to the drug manufacturing companies for *prima facie* not obtaining price approval even after crossing the limit of Rs. 50 lakhs in sales turnover. Names of such companies were given in reply to Rajya Sabha Unstarred Question No. 1557 answered on 2nd December, 1985. Names of the products of such companies having sales turnover of Rs. 1 crore or more $^{nave\ not}$ been identified a$_s$ the sales turnover of formulations is not monitored.

Show cause notices to drug manufacturers

2193. SHRIMATI MONIKA DAS: Will the Minister of INDUSTRY be pleased to refer to the answer to the Unstarred Question 188 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) when were the show cause notices issued to Burroughs Wellcome, Pfizer and Glaxo and when were the explanation of each company received;

(b) what were the main grounds on which each show cause notice was issued;

(c) what are the bulk drugs involved in each case and what is the permitted capacity of each company as well as what was the production of each company during the last three years; year-wise;

(d) whether it is a fact that these companies did not implemented the prices fixed by Government for those drugs and have been charging their own prices up-till today;

(e) whether it is also a fact that over charging is the main consideration of these companies for unauthorised excess pro-

duction at the cost of curtailment of production of essential drugs falling under category I and II; and

(f) if so, what are the details thereof?

THE MINISTER OF STATE IN THE RTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) The desired infoimation is as under:

Name of the company	Date of Issue of show cause notice	Date of receipt of reply
1. M/s Burroughs Wellcome	March, 1984	September, 1984
2. M/s Glaxo Labs.	September, 1984	December, 1984
3. M/s Pfizer	December, 1984	January, 1985

(b) and (c) N_0 final decision has yet been taken on the findings of the Technical Team, as a policy decision is required to be taken.

(d) The requisite information regarding M]i. Burroughs Willcome and Mis. Glaxo has been furnished in reply to Rajya Sabha Unstarred Question No. 161 dated 18-11-1985. The prices charged by M|s. Pfizer Limited for Oxytetracycline and its salts and certain multivitamin formulations, axe in accordance with the orders of the Delhi and Bombay High Court.

(e) and (f) No, Sir. Production of formulations is tailored to market demand.

Price Fiction of products of M|s. Abbott, Lab.

2194. SHRIMATI MONIKA DAS: Will the Minister of INDUSTRY be pleased *to* refer to the answer to Unstarred Question 187 given in the Rajya Sabha on the 18th November, 1985 and state:

(a) when M/s. Abbott Lab. filed material to Government in support of their claim for higher prices of formulations than the prices fixed by Government;

(b) when was the hearing given to Abbott;

(c) whether Government have taken a final decision;

(d) if so. what ar_e the details thereof:

(e) what wa_s the sales turn over of the formulations for which M/s. Abbott Lab; did not'.implement the fixed prices during the last three years, year-wise;

(f) what was the unintended profit made by the company due to non-implementation of prices from the date of fixation order till today; and

(g) what steps have been taken by Government to make these products available at fair prices to public?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH); (a) to (d) After M|s. Abbott submitted their representation, hearing wa_s given to M/s. Abbott Laboratories in August, 1985 and action is already on to take a final decision in the matter.

(e) Sales turnover of $formulation_s$ is not monitored.

(f) The Company is charging the prices as allowed by the Bombay High Court and as $_S$uch there i_s no question of any unintended profit.

(g) The prices of these products are regulated i_n accordance with the Drug (Prises Control) Order, 1979.

Price of Listerin and Pyridiura

2195. SHRIMATI MONIKA DAS: Will the Minister of INDUSTRY be ^eased to refer f> the answer to Unstarred Question 189 given in th_e Rajya Sabha on 18th November. 1985 and state:

(a) whether Government hav_e fixed the $price_s$ of Listerin and Pyridiurn Tablets;